Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18784317 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | July 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18612729 | Materials and Methods for Treatment of Hemoglobinopathies | March 2024 | August 2025 | Abandon | 16 | 2 | 1 | No | No |
| 18593476 | BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTION | March 2024 | March 2026 | Abandon | 24 | 3 | 0 | Yes | No |
| 18405995 | CRISPR/CAS9-BASED REPRESSORS FOR SILENCING GENE TARGETS IN VIVO AND METHODS OF USE | January 2024 | May 2025 | Allow | 17 | 2 | 0 | Yes | No |
| 18513347 | RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOF | November 2023 | November 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18375868 | LYMPHOCYTE TARGETED LENTIVIRAL VECTORS | October 2023 | April 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18371858 | METHODS TO PREVENT TERATOGENICITY OF IMID LIKE MOLECULES AND IMID BASED DEGRADERS/PROTACS | September 2023 | July 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18370000 | USING DREADD FOR NEURONAL MODULATION IN TREATING NEURONAL DISEASES | September 2023 | August 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18470189 | SMALL TYPE II-D CAS PROTEINS AND METHODS OF USE THEREOF | September 2023 | September 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18279201 | LYMPHOCYTE TARGETED LENTIVIRAL VECTORS | August 2023 | February 2026 | Abandon | 30 | 1 | 1 | No | No |
| 18361305 | ANTI-FIBROTIC COMPOSITIONS COMPRISING FENDRR OR FRAGMENTS OR VARIANTS THEREOF AND METHODS OF PRODUCTION AND USE THEREOF | July 2023 | November 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 18359013 | HIGH-TRANSDUCING HSV VECTORS | July 2023 | December 2024 | Allow | 16 | 1 | 0 | No | No |
| 18344732 | HOMOLOGY DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | June 2023 | April 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18138361 | TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASES | April 2023 | June 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18148964 | METHODS AND COMPOSITIONS FOR GENOME EDITING | December 2022 | November 2025 | Abandon | 35 | 2 | 1 | No | No |
| 18146999 | Immunomodulating Gene Therapy | December 2022 | January 2026 | Allow | 36 | 3 | 0 | Yes | No |
| 18052082 | OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE | November 2022 | November 2024 | Allow | 25 | 1 | 0 | No | No |
| 17996832 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS | October 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17951774 | BCMA-Targeted Chimeric Antigen Receptor as well as Preparation Method Therefor and Application Thereof | September 2022 | January 2026 | Allow | 40 | 1 | 0 | No | No |
| 17820178 | BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTION | August 2022 | February 2026 | Abandon | 42 | 1 | 1 | No | No |
| 17816139 | ENHANCED DELIVERY OF VIRAL PARTICLES TO THE STRIATUM AND CORTEX | July 2022 | July 2025 | Allow | 35 | 4 | 0 | Yes | Yes |
| 17614970 | RECOMBINANT ONCOLYTIC VIRUS, PREPARATION METHOD THEREFOR, USE THEREOF AND MEDICINE THEREOF | November 2021 | November 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17613818 | NTRK FUSION MOLECULES AND USES THEREOF | November 2021 | January 2026 | Allow | 50 | 1 | 1 | Yes | No |
| 17610086 | DNA Construct for Diagnosing and Treating Cancer | November 2021 | November 2025 | Allow | 49 | 2 | 1 | No | No |
| 17492465 | ENGINEERED CIRCULAR RNA CIRCMIR-29B AND USE THEREOF IN PREPARATION OF MEDICINE FOR TREATING MUSCLE ATROPHY | October 2021 | September 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17484479 | VAGINAL REJUVENATION METHODS AND DEVICES | September 2021 | January 2025 | Abandon | 39 | 3 | 1 | Yes | No |
| 17395184 | CHIMERIC ANTIGEN RECEPTOR T CELLS AND METHODS OF USE THEREOF | August 2021 | January 2026 | Allow | 54 | 4 | 1 | Yes | No |
| 17384913 | NANOPARTICLE FOR DELIVERING RIBONUCLEOPROTEIN AND USE THEREOF | July 2021 | August 2025 | Abandon | 48 | 4 | 1 | Yes | No |
| 17415860 | COMPLEMENT FACTOR I AND COMPLEMENT FACTOR I COFACTOR, VECTORS ENCODING THEREFOR AND THERAPEUTIC USE | June 2021 | March 2026 | Allow | 57 | 2 | 1 | Yes | No |
| 17339755 | METHOD AND DEVICE FOR DRUG SCREENING | June 2021 | April 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17294031 | Materials and Methods for Pathologies in Muscle following Injury, Disease or Aging | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17293469 | METHOD FOR TREATMENT OF AUTISM SPECTRUM DISORDER, MOUSE FOR MONITORING AUTISM SPECTRUM DISORDER, AND METHOD FOR SCREENING CANDIDATE MATERIAL FOR PREVENTION OR TREATMENT OF AUTISM SPECTRUM DISORDER | May 2021 | August 2025 | Allow | 51 | 4 | 1 | Yes | No |
| 17245431 | DLGAP2 AS A THERAPEUTIC TARGET FOR AND ALZHEIMER'S DISEASE AND AGE-RELATED COGNITIVE DECLINE | April 2021 | October 2025 | Abandon | 54 | 3 | 1 | No | No |
| 17195357 | METHOD OF PRODUCING CAR-T CELLS, NUCLEIC ACID-INTRODUCING CARRIER AND KIT | March 2021 | April 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17271314 | In Vivo Genetic Engineering of Antigen Responsive Cells | February 2021 | May 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17180406 | METHODS FOR ASSESSING TRANSENDOTHELIAL BARRIER INTEGRITY | February 2021 | February 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17268908 | METHODS AND COMPOSITIONS FOR TREATMENT OF SOLID CANCERS AND MICROBIAL INFECTION | February 2021 | March 2026 | Abandon | 60 | 3 | 1 | No | No |
| 17267602 | METHOD FOR TRANSFECTION INTO CARDIOMYOCYTES USING CATIONIC LIPID | February 2021 | July 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 17263435 | Heterorhabditis Bacteriophora with Enhanced Shelf-Life | January 2021 | February 2025 | Allow | 49 | 1 | 1 | No | No |
| 17262900 | METHOD FOR GENE TRANSFER INTO GAMMA-DELTA TYPE T CELL | January 2021 | June 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 17108060 | TREATMENT OF AN OCULAR INFECTION, COMPOSITION AND METHODS THEREOF | December 2020 | September 2025 | Allow | 57 | 4 | 1 | Yes | No |
| 17072591 | HETEROZYGOUS TRANSGENIC ANIMAL | October 2020 | April 2025 | Abandon | 54 | 6 | 1 | Yes | No |
| 17045802 | Genetically Modified T-Cells and PI3K/AKT Inhibitors For Cancer Treatment | October 2020 | November 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16982383 | ALZHEIMERS DISEASE ANIMAL MODEL AND USE THEREOF | September 2020 | February 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 16968990 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR ANTIBODY AND FUSION PROTEIN PRODUCTION | August 2020 | January 2026 | Abandon | 60 | 5 | 1 | No | No |
| 16962005 | CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING CEDNA VECTORS | July 2020 | February 2025 | Allow | 55 | 2 | 1 | No | No |
| 16783148 | GENE THERAPY SYSTEMS AND RELATED METHODS FOR TREATMENT OF HEARING LOSS | February 2020 | April 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16625542 | Compositions and Methods for Efficacy Enhancement of T-Cell Based Immunotherapy | December 2019 | July 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16619898 | ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION | December 2019 | April 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16616302 | Genetic Construct | November 2019 | February 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16658663 | GENE THERAPY TARGETING THE NEONATAL FORM OF NAV1.5 FOR TREATING CANCER | October 2019 | February 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16580996 | METHOD AND COMPOSITION FOR ENDOGENOUS PRODUCTION OF CONSTITUTIVELY ACTIVATED RECEPTORS, AND RECEPTORS WITH BROADER BINDING RANGES OR HIGHER AFFINITY THAN NATIVE RECEPTORS | September 2019 | November 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16534667 | METHODS TO MODULATE PROTEIN TRANSLATION EFFICIENCY | August 2019 | June 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16480541 | EXPRESSION VECTOR FOR CHOLESTEROL 24-HYDROLASE IN THERAPY OF POLYGLUTAMINE REPEAT SPINOCEREBELLAR ATAXIAS | July 2019 | July 2024 | Allow | 59 | 3 | 0 | Yes | Yes |
| 16451906 | COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS | June 2019 | February 2024 | Abandon | 56 | 4 | 1 | No | Yes |
| 16338295 | VIRAL VECTORS FOR NUCLEAR REPROGRAMMING | March 2019 | September 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16318745 | THERAPEUTIC APPLICATIONS OF CPF1-BASED GENOME EDITING | January 2019 | October 2022 | Allow | 45 | 3 | 1 | Yes | No |
| 15774491 | IMPROVED PARAMYXOVIRUS VECTOR | January 2019 | December 2024 | Allow | 60 | 5 | 1 | Yes | Yes |
| 15771925 | GENERATION OF ADULT-LIKE HEART MUSCLE FROM HUMAN PLURIPOTENT STEM CELLS | January 2019 | August 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16310207 | TRUNCATED DYSFERLIN FOR TREATMENT OF DYSFERLINOPATHY | December 2018 | December 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16309289 | ERYTHROID-SPECIFIC PROMOTER AND METHOD OF USE THEREOF | December 2018 | August 2025 | Abandon | 60 | 5 | 1 | No | Yes |
| 16085553 | GENERATION OF MIDBRAIN-SPECIFIC ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | September 2018 | May 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 15999281 | COMPOSITIONS AND METHODS OF USING STAT1/3 INHIBITORS WITH ONCOLYTIC HERPES VIRUS | August 2018 | December 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16072674 | GENETIC, DEVELOPMENTAL AND MICRO-ENVIRONMENTAL PROGRAMS IN IDH-MUTANT GLIOMAS, COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF | July 2018 | February 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16068929 | DIFFERENTIATION INDUCTION FROM HUMAN PLURIPOTENT STEM CELLS INTO HYPOTHALAMIC NEURONS | July 2018 | April 2025 | Allow | 60 | 7 | 1 | Yes | No |
| 16067761 | METHOD FOR PREPARING 3D CARTILAGE ORGANOID BLOCK | July 2018 | September 2023 | Abandon | 60 | 6 | 0 | Yes | No |
| 16065201 | MEDICAMENT FOR TREATING CEREBRAL INFARCTION | June 2018 | April 2025 | Abandon | 60 | 8 | 0 | Yes | No |
| 15996337 | COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY | June 2018 | April 2025 | Allow | 60 | 6 | 2 | Yes | No |
| 15775301 | COMPOSITIONS AND METHODS FOR INCREASING HEPATOCYTE FUNCTIONAL LIFETIME IN VITRO | May 2018 | September 2025 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 15772301 | ADENOVIRUS CONTROL VIRUS | April 2018 | August 2025 | Abandon | 60 | 8 | 1 | Yes | No |
| 15769873 | CELL BANK OF HIGH CONCENTRATION ADIPOSE-DERIVED STEM CELL COMPOSITION AND RELATED METHODS | April 2018 | June 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 15769615 | SYNTHETIC COMBINATORIAL AAV3 CAPSID LIBRARY | April 2018 | July 2024 | Allow | 60 | 4 | 2 | Yes | No |
| 15950383 | METHOD FOR SUPPRESSION OF OR PROTECTION FROM ISCHEMIA/REPERFUSION INJURY OF ORGANS FOR TRANSPLANTATION | April 2018 | May 2025 | Abandon | 60 | 5 | 1 | No | No |
| 15940553 | CELL THERAPY FOR PATIENTS | March 2018 | July 2025 | Allow | 60 | 9 | 0 | Yes | Yes |
| 15764275 | METHODS AND ARTICLES OF MANUFACTURE FOR THE TREATMENT OF ANIMALS | March 2018 | December 2024 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 15934029 | MACRO TISSUE EXPLANT, METHODS AND USES THEREFOR | March 2018 | January 2025 | Abandon | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NICOL, ALEXANDER W.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NICOL, ALEXANDER W works in Art Unit 1634 and has examined 55 patent applications in our dataset. With an allowance rate of 50.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.
Examiner NICOL, ALEXANDER W's allowance rate of 50.9% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NICOL, ALEXANDER W receive 3.95 office actions before reaching final disposition. This places the examiner in the 97% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by NICOL, ALEXANDER W is 10000 months. This places the examiner in the 0% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +56.4% benefit to allowance rate for applications examined by NICOL, ALEXANDER W. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.4% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 94.7% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.